IGF1R and breast carcinoma: Trastuzumab-induced resistance through various receptor tyrosine kinases including IGF1R and HER3 has been described in ovarian and breast cancer [37, 38], and the latter study also described antitumor activity of a combination of trastuzumab and a HER3 inhibitor on trastuzumab-resistant cells.